Proton MR spectroscopic imaging in multiple sclerosis

Neuroradiology

Volumn 44, Issue 1, 2002, Pages 37-42

  Tedeschi, G ^a,b   Bonavita, S ^a,b   McFarland, H F ^c   Richert, N ^c   Duyn, J H ^c   Frank, J A ^c  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Multiple sclerosis; Proton magnetic resonance spectroscopy

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; INTERFERON BETA SERINE; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; AXONAL INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMAGING SYSTEM; MALE; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEUROCHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; WHITE MATTER;

ADULT; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 0036943575     PISSN: 00283940     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002340100584     Document Type: Article

References (40)

1. Sobel RA (1995) The pathology of multiple sclerosis. Neurol Clin 13: 1-21
2. Sanders V, Conrad AJ, Tourtelotte WW (1993) On classification of post-mortem multiple sclerosis plaques for neuroscientists. J Neuroimmunol 46: 207-216
3. Prineas JW, Barnard RO, Revesz T, et al (1993) Multiple sclerosis: Pathology of recurrent lesions. Brain 116: 681-693
4. Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H (1996 Distinct patterns of multiple sclerosis pathology indicate heterogeneity in pathogenesis. Brain Pathol 6: 259-274
5. Charcot M (1868) Histologic: de la sclérose en plaque. Gaz Hosp 141: 554-558
6. Fergusson B, Mattszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120: 714-725
7. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Lars BO (1998) Axonal transection in the lesions of multiple sclerosis. N Eng J Med 338: 278-285
8. Arnold DL, Matthews PM, Francis G, et al (1992) Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 31: 235-241
9. Arnold DL, Ries GT, Matthews PM, et al (1994) Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 36: 76-82
10. Bruhn H, Frahm J, Merboldt KD, et al (1992) Multiple sclerosis in children: cerebral metabolic alteration monitored by localized proton magnetic resonance spectroscopy in vivo. Ann Neurol 32: 140-150
11. Davie CA, Barker GJ, Thompson AJ, et al (1997) 1H magnetic resonance spectroscopy of chronic white-matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 63: 736-742
12. De Stefano N, Matthews PM, Antel JP, et al (1995) Chemical pathology of acute demyelinating lesions and its correlations with disability. Ann Neurol 38: 901-909
13. Matthews PM, Pioro E, Narayanan S, et al (1996) Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 119: 715-722
14. Narayana PA, Doyle TJ, Lai D, Wolinsky J (1998) Serial proton magnetic resonance spectroscopic imaging contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 43: 56-71
15. Narayanan S, Fu L, Pioro E, et al (1997) Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 41: 385-391
16. Pan JW, Hetherington HP, Vaughan JT, et al (1996) Evaluation of multiple sclerosis 1H spectroscopic imaging at 4.1 T. Magn Reson Med 36: 72-77
17. Reddy H, Narayanan S, Matthews PM, et al (2000) Relating axonal injury to functional recovery in MS. Neurology 54: 236-239
18. Gonen O, Catalaa I, Babb JS, Ge Y, et al. (2000) Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 54: 15-19
19. Leary SM, Davie CA, Parker GJ, et al (1999) 1H magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis. J Neurol 246: 1023-1026
20. Silber E, Sharief MK (1999) Axonal degeneration in the pathogenesis of multiple sclerosis. J Neurol Sci 170: 11-18
21. Davie CA, Silver NC, Barker GJ, et al (1999) Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? J Neurol Neurosurg Psychiatry 67: 710-715
22. Bitsch A, Bruhn H, Vougioukas V, et al (1999) Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR 20: 1619-1627
23. Tourbah A, Stievenart JL, Gout O, et al (1999) Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis. Neurology 53: 1091-1097
24. Sarchielli P, Presciutti O, Pelliccioli GP, et al (1999) Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 122: 513-516
25. van Walderveen MA, Barkhof F, Pouwels PJ, et al (1999) Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 46: 79-87
26. De Stefano N, Matthews PM, Fu L, et al (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121: 1469-1477
27. Fu L, Matthews PM, De Stefano N, et al (1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121: 103-113
28. Falini A, Calabrese G, Filippi M, et al (1998) Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. AJNR 19: 223-229
29. RooneyWD, Goodkin DE, Schuff N, et al (1997) 1H-MRSI of normal appearing white matter in multiple sclerosis. Multiple Sclerosis 3: 231-237
30. Duyn JH, Gillen J, Sobering G, van Zijl PC, Moonen CTW (1993 Multisection proton MR spectroscopic imaging of the brain. Radiology 188: 277-282
31. Tedeschi G, Bertolino A, Righini A, et al (1995) Brain regional distribution pattern of metabolite signal intensities in young adults by proton magnetic resonance spectroscopic imaging. Neurology 45: 1384-1391
32. Stone, LA, Frank JA, Albert, PS, et al (1997) Characterization of MRI response to treatment with interferon beta 1b: contrast enhancing MRI lesion frequency as a primary outcome measure. Neurology 49: 862-869
33. Urenjak J, Williams SR, Gadian DG, Noble M (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13: 981-989
34. Moffett JR, Namboodiri MA, Cangro CB, Neale JH (1991) Immunohistochemical localization of N-acetylaspartate in rat brain. NeuroReport 2: 131-134
35. Moffett JR, Namboodiri MA, Neale JH (1993) Enhanced carbodiimide fixation for immunohistochemistry: application to the comparative distributions of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat brain. J Histochem Cytochem 41: 559-570
36. Rango M, Spagnoli D, Tomei G, et al (1995) Central nervous system trans-synaptic effects of acute axonal injury: a 1H magnetic resonance spectroscopy study. Magn Reson Med 33: 595-600
37. Vion-Dury J, Nicoli F, Salvan AM, et al (1995) Reversal of brain metabolic alterations with zidovudine detected by proton localized magnetic resonance spectroscopy. Lancet 345: 60-61
38. Miller BL, Chang L, Booth R, et al (1996) In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci 58: 1929-1935
39. Barker PB, Breiter SN, Soher BJ, et al ( 1994) Quantitative proton spectroscopy of canine brain: in vivo and in vitro correlations. Magn Reson Med 32: 157-163
40. Allen IV, McKeown SR (1979) A histological, histochemical and biochemical of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 41: 81-91